Results 181 to 190 of about 510,697 (405)

POS1071 DETERMINATION OF THE RELIABILITY AND VALIDITY OF THE BETY-BIOPSYCHOSOCIAL QUESTIONNAIRE IN PATIENTS WITH A DIAGNOSIS OF PSORIATIC ARTHRITIS [PDF]

, 2021
Süleyman Bulut, Edibe Ünal, Jale Karakaya, Umut Kalyoncu   +3 more
openalex   +1 more source

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon, Karishma S. Shah, Sidharth Chand, Bonnie Lee, Janellen Smith, Michelle S. Min   +5 more
wiley   +1 more source

Assessing the Effect of Adalimumab in Granuloma Annulare: A Case Series and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Granuloma annulare (GA) is a benign granulomatous skin disorder for which standardized treatment guidelines are lacking due to limited evidence. Adalimumab, a TNF‐α inhibitor, shows promise as a therapeutic option due to its potential to disrupt GA granulomas.
Adriana Caixinha Valorenzos, Line Kibsgaard, Trine Bertelsen   +2 more
wiley   +1 more source

Correction to: Risk Factors for Progression from Subclinical to Clinical Phase of Psoriatic Arthritis: A Case–Control Study [PDF]

, 2021
Yiyi Wang, Li Ding, Jihui Chen, Lingyan Zhang, Min Yang, Zhibin Liu, Liang Cheng, Tianjiao Lan, Gaojie Li, Yuanxia Gu, Yi Liu, Wei Li   +11 more
openalex   +1 more source

Serum and Fecal Calprotectin Levels Do Not Alter Significantly in Patients With Psoriasis Switching to Brodalumab After Loss of Effect From TNF‐α Inhibitors

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory skin disease often associated with systemic conditions like psoriatic arthritis and inflammatory bowel disease (IBD). Calprotectin, an inflammatory biomarker commonly used in IBD, has also been found elevated in psoriasis.
Admir Vižlin, Hans‐Peter Claesson, Ylva Andersch Björkman, Martin Gillstedt, Eva Klingberg, Emanuela Micu, Amra Osmančević   +6 more
wiley   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

JEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge, Charlotte Vogel, Theresa Hempel, Basil Signer, Nikhil Yawalkar, Kristine Heidemeyer   +5 more
wiley   +1 more source

Epidemiology, genetics and management of psoriatic arthritis 2013: focus on developments of who develops the disease, its clinical features, and emerging treatment options

Psoriasis: Targets and Therapy, 2013
Muhammad Haroon,1 Oliver FitzGerald,1 Robert Winchester2 1Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland; 2Division of Rheumatology, Columbia University College of Physicians and Surgeons, New York, NY, USA Abstract ...
Haroon M, FitzGerald O, Winchester R
doaj  

Polymorphism in MICA rather than HLA-B/C genes is associated with psoriatic arthritis in the Jewish population

, 2001
Segundo González, Chaim Brautbar, Jesús Martı́nez-Borra, Antonio López‐Vázquez, R Segal, Miguel Ángel Blanco-Gelaz, Claes D. Enk, Cilly Safriman, Carlos López‐Larrea   +8 more
openalex   +2 more sources

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

308G/A and 238G/A polymorphisms in the TNF-α gene may not contribute to the risk of arthritis among Turkish psoriatic patients

, 2016
Selda Işık, Fatma Sılan, Sevilay Kılıç, Meliha Merve Hız, Zerrin Öğretmen, Öztürk Özdemir   +5 more
openalex   +1 more source